A potential Parkinson’s treatment called cerebral dopamine neurotrophic factor (CDNF) continues to be safe and well tolerated by patients with moderate disease using it for up to one year in a Phase 1/2 trial, and shows a promising potential to ease motor symptoms and slow disease progression, Herantis Pharma, its developer, reported
Potential Parkinson’s Treatment, CDNF, Sh... - Cure Parkinson's
Potential Parkinson’s Treatment, CDNF, Shows Safety and Tolerability at One Year
Written by
JayPwP
To view profiles and participate in discussions please or .
Read more about...
15 Replies
•
Probably the biggest downside is that it requires brain surgery.
So did GDNF
Exactly!
But the delivery port is temporary. Look at the videos in my reply on GDNF here:
Have you heard about fast w
JayPwP in reply to
Fast walking?
Less intrusive..
As per John Pepper theory, fast walking boosts GDNF, a natural brain protein.
This is CDNF, this is different than GDNF
in reply to WinnieThePoo
Reverses essential tremor
Hikoi in reply to
I wonder what it reverses as Mr P was able to exercise intensively for 90 mins a day but apparently it didnt help.. only walking fast and an antidepressant did. He never stopped moving and didnt need to learn how to walk again, I believe a certain author manipulated his story to fit the author’s thesis.
Not what you're looking for?
You may also like...
A potential case of remission of Parkinson’s disease
Morgan and Patrick McNamaraA potential case of remissionof Parkinson’s diseaseDOI 10.1515/jcim-2016
Hot off the press. Randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease.
replenishment therapy using nicotinamide riboside (NR) shows promise for Parkinson’s disease (PD)...
Studies Show Chinese Herb Effective in Treatment of Parkinson’s
associated with Parkinson’s disease....
FDA Approves Focused Ultrasound Treatment for Parkinson’s Disease
s-focused-ultrasound-treatment-for-parkinsons-disease...
Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS Trial
Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS Trial...